Table of Contents
- Clinical trial overview
- Conditions being studied
- Study designs, phases, and treatments
- Who can participate
- Main outcomes measured
- What these trials are trying to show
Clinical trial overview
Several interventional studies are investigating Alks 2680 in people with sleep disorders that cause strong daytime sleepiness.[1][2][3][4] The studies include both short-term and long-term research, and they are designed to look at safety, effectiveness, and tolerability.[1][2]
Conditions being studied
The trials focus on idiopathic hypersomnia, narcolepsy type 1, and narcolepsy type 2.[1][2][3][4] Idiopathic hypersomnia means a person has severe sleepiness, but the cause is not known.[1] Narcolepsy is another sleep disorder linked to excessive daytime sleepiness, and the trials separate type 1 and type 2 when needed.[2][3]
Study designs, phases, and treatments
Three of the studies are Phase 2 trials, which are usually used to learn more about early effectiveness and safety.[1][3][4] One study is a Phase 4 long-term trial, which is focused on safety and tolerability over time.[2]
The idiopathic hypersomnia study includes Alks 2680 doses of 10 mg, 14 mg, and 18 mg, plus a placebo that matches the study drug.[1] The narcolepsy type 2 study includes 10 mg, 14 mg, and 18 mg doses, also with placebo.[3] The narcolepsy type 1 study includes 4 mg, 6 mg, and 8 mg doses, with placebo.[4] The long-term study includes several oral dose levels, from 4 mg to 18 mg.[2]
Who can participate
The study populations are people with the conditions named in each trial: idiopathic hypersomnia, narcolepsy type 1, or narcolepsy type 2.[1][2][3][4] The source data does not give full join rules such as age limits or other medical requirements, so only the listed patient groups can be confirmed here.[1][2][3][4]
Main outcomes measured
The trials mainly measure changes in sleepiness and safety-related outcomes.[1][2][3][4] In the idiopathic hypersomnia and narcolepsy type 1 and 2 studies, the Epworth Sleepiness Scale (ESS) is used to track change from the start of the study to later weeks.[1][3] The narcolepsy type 1 and type 2 studies also use the Maintenance of Wakefulness Test (MWT), which checks how well a person can stay awake in quiet conditions.[3][4]
The long-term Phase 4 study measures treatment-emergent adverse events, meaning health problems that begin or get worse after treatment starts.[2] This helps researchers understand longer-term safety and tolerability in a larger group of people.[2]
What these trials are trying to show
Overall, the studies are trying to find out whether Alks 2680 can reduce excessive daytime sleepiness in people with idiopathic hypersomnia and narcolepsy.[1][3][4] They also aim to show whether the treatment is safe enough for short-term use and how it performs during longer follow-up.[2]
